Shandong Xinhua Pharmaceutical Company Limited (XIN) — Cash Flow Quality Index
Shandong Xinhua Pharmaceutical Company Limited (XIN) has a Cash Flow Quality Index of 0.46x as of September 2023. Operating cash flow of €56.11 Million is below net income of €122.16 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore investment intensity of Shandong Xinhua Pharmaceutical Company L to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Shandong Xinhua Pharmaceutical Company Limited Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Shandong Xinhua Pharmaceutical Company Limited across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Shandong Xinhua Pharmaceutical Company L tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Shandong Xinhua Pharmaceutical Company Limited (2013–2025)
Year-by-year earnings quality comparison for Shandong Xinhua Pharmaceutical Company Limited. For live market cap and the full company financial profile, see XIN market cap.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.84x | €533.73 Million | €289.89 Million | ▲ +135.4% |
| 2024 | 0.78x | €367.61 Million | €470.02 Million | ▲ +46.4% |
| 2023 | 0.53x | €265.28 Million | €496.51 Million | ▼ -71.0% |
| 2022 | 1.84x | €758.24 Million | €411.19 Million | ▲ +148.0% |
| 2021 | 0.74x | €259.12 Million | €348.55 Million | ▼ -42.5% |
| 2020 | 1.29x | €420.19 Million | €324.86 Million | ▲ +11.4% |
| 2019 | 1.16x | €348.27 Million | €299.97 Million | ▼ -8.5% |
| 2018 | 1.27x | €323.91 Million | €255.31 Million | ▼ -31.8% |
| 2017 | 1.86x | €389.97 Million | €209.59 Million | ▼ -48.2% |
| 2016 | 3.59x | €439.35 Million | €122.27 Million | ▼ -14.4% |
| 2015 | 4.20x | €348.64 Million | €83.06 Million | ▼ -38.5% |
| 2014 | 6.83x | €346.34 Million | €50.73 Million | ▲ +154.6% |
| 2013 | 2.68x | €104.99 Million | €39.15 Million | — |